CRVS - CIK 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$32.80M | -$25.42M | -$23.93M | -$27.02M | -$36.72M | -$34.78M |
| Capital expenditure | $174.00K | - | $34.00K | $269.00K | $5.00K | $76.00K |
| Investing cash flow | -$7.80M | -$27.48M | $15.54M | -$23.28M | $21.56M | $44.77M |
| Dividends paid | $0.00 | $0.00 | $0.00 | - | - |
Corvus Pharmaceuticals, Inc. reported operating cash flow of -$32.80M for fiscal year 2025. That is down 29.0% from -$25.42M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$27.86M (FY 2016) to -$32.80M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $36.43M | $49.03M | $7.86M | $0.00 | $62.16M | $1.31M |